NO963064D0 - Behandling av normotensive glaukoma med angiotensin-II-antagonister - Google Patents

Behandling av normotensive glaukoma med angiotensin-II-antagonister

Info

Publication number
NO963064D0
NO963064D0 NO963064A NO963064A NO963064D0 NO 963064 D0 NO963064 D0 NO 963064D0 NO 963064 A NO963064 A NO 963064A NO 963064 A NO963064 A NO 963064A NO 963064 D0 NO963064 D0 NO 963064D0
Authority
NO
Norway
Prior art keywords
pct
treatment
angiotensin
antagonists
sec
Prior art date
Application number
NO963064A
Other languages
English (en)
Other versions
NO963064L (no
Inventor
Alicia Huxley
Georg Mathis
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO963064L publication Critical patent/NO963064L/no
Publication of NO963064D0 publication Critical patent/NO963064D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
NO963064A 1994-02-08 1996-07-23 Behandling av normotensive glaukoma med angiotensin-II-antagonister NO963064D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810071 1994-02-08
PCT/IB1995/000056 WO1995021609A1 (en) 1994-02-08 1995-01-26 Treatment of normotensive glaucoma with angiotensin ii antagonists

Publications (2)

Publication Number Publication Date
NO963064L NO963064L (no) 1996-07-23
NO963064D0 true NO963064D0 (no) 1996-07-23

Family

ID=8218203

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963064A NO963064D0 (no) 1994-02-08 1996-07-23 Behandling av normotensive glaukoma med angiotensin-II-antagonister

Country Status (17)

Country Link
US (1) US5889020A (no)
EP (1) EP0743852B1 (no)
JP (1) JPH09508641A (no)
CN (1) CN1140409A (no)
AT (1) ATE300287T1 (no)
AU (1) AU1423795A (no)
CA (1) CA2181461A1 (no)
CY (1) CY2567B1 (no)
DE (1) DE69534339T2 (no)
DK (1) DK0743852T3 (no)
ES (1) ES2243933T3 (no)
FI (1) FI963083A (no)
IL (1) IL112520A0 (no)
MX (1) MX9603259A (no)
NO (1) NO963064D0 (no)
WO (1) WO1995021609A1 (no)
ZA (1) ZA95958B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
RU2123847C1 (ru) * 1994-03-16 1998-12-27 Санкио Компани Лимитед Лекарственное средство и способ лечения повышенного глазного давления и/или глаукомы
JPH10167961A (ja) * 1996-12-11 1998-06-23 Santen Pharmaceut Co Ltd 緑内障治療剤
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
SG142116A1 (en) * 1998-07-10 2008-05-28 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker
EP1197223B1 (en) 1999-04-28 2005-02-16 Takeda Pharmaceutical Company Limited Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
PL200009B1 (pl) 1999-06-11 2008-11-28 Sankyo Co Kompozycja obniżająca ciśnienie wewnątrzgałkowe oraz zastosowanie antagonisty angiotensyny II do obniżania ciśnienia wewnątrzgałkowego
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
WO2001030388A1 (fr) * 1999-10-25 2001-05-03 Senju Pharmaceutical Co., Ltd. Agents permettant de soulager la tension d'un muscle ciliaire
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
EP1262180A4 (en) 2000-02-18 2005-06-01 Takeda Pharmaceutical TNF-ALPHA HEMMER
WO2002045748A1 (fr) * 2000-12-05 2002-06-13 Sankyo Company, Limited Compositions d'abaissement de la tension oculaire pour administration topique
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP1614428A4 (en) * 2003-04-15 2010-01-06 Sankyo Co MEDICAMENT FOR THE PREVENTION OR TREATMENT OF ANGIOGENIC OCULAR DISEASES
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
US20060160871A1 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
PT1872783E (pt) * 2005-04-21 2012-01-16 Santen Pharmaceutical Co Ltd Agente terapêutico para distúrbio queratoconjuntivo
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
EP2376101B1 (en) * 2008-12-29 2015-12-02 Trevena, Inc. Beta-arrestin effectors and compositions and methods of use thereof
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
JP2017506235A (ja) 2014-02-07 2017-03-02 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． ベータ−アレスチンエフェクターの結晶性および非晶質形態
AU2015264367A1 (en) 2014-05-19 2016-12-15 Trevena, Inc. Synthesis of Beta-Arrestin Effectors
CN105188250A (zh) * 2015-09-09 2015-12-23 上海联影医疗科技有限公司 靶组件以及具有该靶组件的直线加速器
CN105244434B (zh) * 2015-10-13 2017-10-10 北京科技大学 一种C掺杂ZnO热电材料的制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430709A3 (en) * 1989-12-01 1992-02-12 Glaxo Group Limited Benzthiophen derivatives
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma

Also Published As

Publication number Publication date
MX9603259A (es) 1997-03-29
EP0743852A1 (en) 1996-11-27
CA2181461A1 (en) 1995-08-17
ATE300287T1 (de) 2005-08-15
ZA95958B (en) 1995-08-08
EP0743852B1 (en) 2005-07-27
DE69534339T2 (de) 2006-05-24
IL112520A0 (en) 1995-05-26
CY2567B1 (en) 2008-07-02
WO1995021609A1 (en) 1995-08-17
JPH09508641A (ja) 1997-09-02
AU1423795A (en) 1995-08-29
NO963064L (no) 1996-07-23
DE69534339D1 (de) 2005-09-01
US5889020A (en) 1999-03-30
FI963083A (fi) 1996-08-07
DK0743852T3 (da) 2005-10-17
FI963083A0 (fi) 1996-08-05
CN1140409A (zh) 1997-01-15
ES2243933T3 (es) 2005-12-01

Similar Documents

Publication Publication Date Title
CY2567B1 (en) Treatment of normotensive glaucoma with angiotensin II antagonists
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
TR200101859T2 (tr) Kemokin alıcı aktivitesinin modülatörleri olarak N-üreidoalkil-piperidinler
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
MY117251A (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
WO1999024051A3 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
ES2185660T3 (es) Nuevo uso de dexmedetomidina.
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
DK0711283T3 (da) Tetrahydro-1H-benzazepinoner og hexahydroazepinoner som selektive cholecystokinin-B-receptorantagonister
DE69412073T2 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
SE9302218D0 (sv) New use
SE9404438D0 (sv) New process
CA2228572A1 (en) Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi